Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 3000+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | August 12, 2026

Aug 12, 2026

•

3 min read

Biotech & Pharma Updates | August 12, 2026

🧬 BridgeBio's Attruby hits $222M quarterly sales, nearing blockbuster status as ATTR stabilizer-first market emerges, Definium Therapeutics' DT120 (LSD) succeeds in Ph3 trial for generalized anxiety disorder, InduPro raises $77M Series B, backed by Sanofi and Lilly, funding cancer pipeline advancement

Christian Cuchapin, +1

Biotech & Pharma Updates | August 11, 2026

Aug 11, 2026

•

3 min read

Biotech & Pharma Updates | August 11, 2026

🧬 Bristol Myers Squibb commits $2.3B to build Houston manufacturing campus, creating 2,500 jobs, Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.3B, expanding rare epilepsy pipeline, Vaderis Therapeutics raises $152M Series B to advance AKT-targeting HHT treatment

Christian Cuchapin, +1

Biotech & Pharma Updates | August 10, 2026

Aug 10, 2026

•

3 min read

Biotech & Pharma Updates | August 10, 2026

🧬 Novo Nordisk, Amazon Web Services partner on AI drug discovery, launch London innovation hub, Silence Therapeutics' (divesiran) hits primary endpoint in Ph2 trial targeting TMPRSS6 for polycythemia vera, AbCellera's (ABCL635) Ph2 data surpass rivals in NK3R-targeting therapy for menopause-related hot flashes

Christian Cuchapin, +1

Long Form Content

Chapter Two: What Comes After Psychedelics?

Aug 8, 2026

•

6 min read

Chapter Two: What Comes After Psychedelics?

🧬 Human experience as a key driver in drug (re)discovery.

Anis Fahandej-Sadi

Biotech & Pharma Updates | August 7, 2026

Aug 7, 2026

•

3 min read

Biotech & Pharma Updates | August 7, 2026

🧬 Replimune's Tudriqev (RP1) wins FDA accelerated approval for advanced melanoma post-PD-1 therapy failure, Tarsus Pharmaceuticals acquires Alkeus Pharmaceuticals for up to $800M to develop Stargardt disease treatment, Latigo Biotherapeutics raises $345.6M IPO to advance non-opioid pain drug pipeline

Christian Cuchapin, +1

Biotech & Pharma Updates | August 6, 2026

Aug 6, 2026

•

3 min read

Biotech & Pharma Updates | August 6, 2026

🧬 FDA approves Moderna's mFLUVISA, first mRNA-based flu vaccine, for seasonal influenza prevention in adults 50 and older, LifeMine Therapeutics raises $263M in venture financings, advancing novel organ transplant treatment, Schrödinger expands Bristol Myers Squibb partnership with large-scale Bunsen AI co-scientist deployment

Christian Cuchapin, +1

Biotech & Pharma Updates | August 5, 2026

Aug 5, 2026

•

3 min read

Biotech & Pharma Updates | August 5, 2026

🧬 Eli Lilly posts record $23B Q2 revenue, driven by Mounjaro and Zepbound despite slower Foundayo launch, Icon, Anthropic partner to deploy Claude AI into clinical trials via multi-year collaboration, Gilead Sciences' HIV prevention franchise surpasses $1B quarterly sales, raises full-year HIV growth guidance

Christian Cuchapin, +1

Biotech & Pharma Updates | August 4, 2026

Aug 4, 2026

•

3 min read

Biotech & Pharma Updates | August 4, 2026

🧬 Otsuka's Voyxact (sibeprenlimab) stabilizes kidney function decline to normal levels in Ph3 immunoglobulin A nephropathy trial, Pathos AI, AstraZeneca, Jiangsu Alphamab Biopharmaceuticals ink dual breast cancer deals, $125M upfront, $2.093B milestones, Merck & Co. raises 2026 sales guidance to $67.3B as Keytruda, Winrevair, and Lipfendra drive growth

Christian Cuchapin, +1

Biotech & Pharma Updates | August 3, 2026

Aug 3, 2026

•

3 min read

Biotech & Pharma Updates | August 3, 2026

🧬 Supernus Pharmaceuticals, Indivior Pharmaceuticals merge in all-stock deal, creating $2.2B CNS company with 11 approved drugs, Novartis' Pluvicto (lutetium vipivotide tetraxetan) wins FDA approval for PSMA-positive metastatic hormone-sensitive prostate cancer label expansion, AstraZeneca, Bristol Myers Squibb reportedly in early-stage merger talks valuing combined entity at $400B

Christian Cuchapin, +1

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | August 12, 2026

Biotech & Pharma Updates | August 11, 2026

Biotech & Pharma Updates | August 10, 2026

Chapter Two: What Comes After Psychedelics?

Biotech & Pharma Updates | August 7, 2026

Biotech & Pharma Updates | August 6, 2026

Biotech & Pharma Updates | August 5, 2026

Biotech & Pharma Updates | August 4, 2026

Biotech & Pharma Updates | August 3, 2026

TLDR Biotech

FAQ

Media Partners